All PlansCoverageMedium impact
Intensity-Modulated Radiotherapy (IMRT): Abdomen, Pelvis and Chest
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Radiology·Medical Policy
We identified it
Jun 20, 2026
Summary
New medical policy establishes coverage criteria for Intensity-Modulated Radiotherapy (IMRT) for abdomen, pelvis and chest cancers. IMRT is considered medically necessary for anal cancer and select other cancers when standard 3D radiotherapy would cause unacceptable toxicity to surrounding organs.
Action Required
Immediately: Billing and clinical teams must ensure proper documentation of medical necessity for IMRT claims. For abdomen/pelvis cancers (stomach, hepatobiliary, pancreas, esophageal, rectal, gynecologic), obtain dosimetric planning studies showing that standard 3D conformal radiotherapy would exceed normal tissue tolerance doses before billing IMRT. Create checklist for providers to document radiation dose calculations and organ toxicity risks. Claims may be denied without proper medical necessity documentation.